{
    "clinical_study": {
        "@rank": "99082", 
        "arm_group": [
            {
                "arm_group_label": "Eplerenone", 
                "arm_group_type": "Experimental", 
                "description": "Eplerenone 25-50mg daily additionally to standard ACE-inhibition with enalapril 20mg daily"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo additionally to standard ACE-inhibition with enalapril 20mg daily"
            }
        ], 
        "brief_summary": {
            "textblock": "In a prospective single centre placebo-controlled trial over ten weeks, 24 CKD II-III\n      patients (eGFR 30-89 ml/min per 1.73 m2) with DM II will be randomized to enalapril 20mg per\n      day after a two week run-in phase. Thereafter, patients will either receive eplerenone 25mg\n      (n=12) or a placebo (n=12) for eight weeks. Eplerenone will be increased to 50mg under close\n      monitoring of serum potassium levels. Employing a novel mass-spectrometry ( MS)-based\n      method, quantification of up to 10 different Ang metabolites (Ang I, Ang II, Ang 1-7, Ang\n      1-9, Ang 2-10, Ang 1-5, Ang 2-7, Ang 3-7, Ang 3-8 and Ang 2-8) will be performed\n      simultaneously out of blood sera (after run-in phase and after 10 weeks)."
        }, 
        "brief_title": "The EPOCH Study (Eplerenone on Top of ACE Inhibition in Chronic Kidney Disease Patients With Hypertension)", 
        "condition": "CKD II-III", 
        "condition_browse": {
            "mesh_term": "Renal Insufficiency, Chronic"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  CKD II to III and diabetes mellitus type 2\n\n          -  CKD will be defined according to estimated glomerular filtration rate (eGFR) with the\n             MDRD formula\n\n          -  eGFR between 30 and 89 ml/min\n\n          -  albumin excretion rates > 300 mg/24 hours (UACR > 300 mg/gram) or > 200 mg/g if\n             already receiving any RAS blockade Patients should be hypertonic stage I or II\n             according to the European guidelines (Chobanian et al. JAMA  2003)\n\n        Exclusion Criteria:\n\n          -  Age < 18 years\n\n          -  UACR > 3500mg/g\n\n          -  severe hypertension\n\n          -  pregnancy\n\n          -  unwilling or inability to sign the informed consent\n\n          -  coronary heart disease\n\n          -  systolic blood pressure < 130 mmHg\n\n          -  additional RAS interfering drugs (ACEis, ARBs, direct renin inhibitors)\n\n          -  25-hydroxy vitamin D levels below 16.6\u00b18.3 pg/ml\n\n          -  1,25-dihydroxy vitamin D 33.1\u00b115.5 pg/ml\n\n        Intolerance to eplerenon or an excipient of it:\n\n        tablettcore: Lactose-Monohydrat Mikrokristalline Cellulose (E 460) Croscarmellose-sodium\n        (E 468) Hypromellose (E 464) Sodiumdodecylsulfat Talkum (E 553b) Magnesiumstearat (E 470b)\n\n        filmcoat\n\n        Opadry, yellow:\n\n        Hypromellose (E 464) Titandioxid (E 171) Macrogol 400 Polysorbat 80 (E 433) Yellow\n        ironoxide (E 172) Red ironoxide (E 172)\n\n          -  Patients with Serumpotassium > 5,0 mmol/l at start of the treatment\n\n          -  Patients with severe renal insufficiency (eGFR <30ml/min./1.73 m2)\n\n          -  Patients with severe liver insufficiency (Child-Pugh class C)\n\n          -  Patients taking potassium saving diuretics, potassium supplements or strong\n             CYP3A4-inhibitors (z. B. Itraconazol, Ketoconazol, Ritonavir, Nelfinavir,\n             Clarithromycin, Telithromycin und Nefazodon)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "April 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01832558", 
            "org_study_id": "EudraCT: 2012-002175-34"
        }, 
        "intervention": [
            {
                "arm_group_label": "Eplerenone", 
                "intervention_name": "Eplerenone", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Eplerenone"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 15, 2013", 
        "location": {
            "contact": {
                "email": "marcus.saemann@meduniwien.ac.at", 
                "last_name": "Marcus Saemann, MD", 
                "phone": "01/40400/5593"
            }, 
            "facility": {
                "address": {
                    "city": "Vienna", 
                    "country": "Austria", 
                    "zip": "1090"
                }, 
                "name": "Medical University of Vienna"
            }, 
            "investigator": {
                "last_name": "Johannes Kovarik, MD", 
                "role": "Sub-Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Austria"
        }, 
        "number_of_arms": "2", 
        "overall_contact": {
            "email": "marcus.saemann@meduniwien.ac.at", 
            "last_name": "Marcus Saemann, MD", 
            "phone": "0043/404005593"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Austria: Ethikkommission"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "April 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Angiotensin levels (pg/ml) of CKD II-III patients with DM II with eplerenone additional to enalapril in comparison to  patients who receive a placebo on top of enalapril therapy.", 
            "time_frame": "1 year"
        }, 
        "reference": [
            {
                "PMID": "22336987", 
                "citation": "Shavit L, Lifschitz MD, Epstein M. Aldosterone blockade and the mineralocorticoid receptor in the management of chronic kidney disease: current concepts and emerging treatment paradigms. Kidney Int. 2012 May;81(10):955-68. doi: 10.1038/ki.2011.505. Epub 2012 Feb 15. Review."
            }, 
            {
                "PMID": "17699311", 
                "citation": "Epstein M, Williams GH, Weinberger M, Lewin A, Krause S, Mukherjee R, Patni R, Beckerman B. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol. 2006 Sep;1(5):940-51. Epub 2006 Jul 19."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01832558"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Medical University of Vienna", 
            "investigator_full_name": "Marcus Saemann", 
            "investigator_title": "Assoc. Prof. Priv.-Doz. Dr.med.univ.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Medical University of Vienna", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Medical University of Vienna", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}